The MATCH (Medication Aids for Tobacco Cessation and Health) Study
Status:
Completed
Trial end date:
2016-12-31
Target enrollment:
Participant gender:
Summary
Clinically proven medications such as nicotine replacement therapy, bupropion and varenicline
are available to help smokers quit but there are not widely used. The primary objective of
this study is to evaluate the real-world long-term effectiveness of of bupropion and
varenicline treatment in a community sample of smokers interested in quitting. The
investigators hypothesize that varenicline treatment will result in higher quit rates at end
of treatment and at one year after treatment compared to bupropion. Smoking status will be
biochemically confirmed at various time points using salivary cotinine measures. Furthermore,
since 50% of the variation in quit success is genetically determined, and the effectiveness
of different cessation medication may differ considerably in sub-groups of smokers carrying
certain genetic variants, the investigators will collect saliva samples from consenting
participants to evaluate the moderating effect of genetics on treatment response.
Phase:
N/A
Details
Lead Sponsor:
Centre for Addiction and Mental Health
Collaborator:
Global Research Awards for Nicotine Dependence (GRAND)